Synthesis of Macrocyclic Organo-peptide Hybrids from Ribosomal Polypeptide Precursors via CuAAC-/Hydrazide-Mediated Cyclization

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1248)

Abstract

Macrocyclic peptides have attracted increasing attention as a potential new source of chemical probes and therapeutics. In particular, their conformationally restricted structure combined with a high degree of functional and stereochemical complexity makes them promising scaffolds for targeting biomolecules with high affinity and selectivity. The exploration of this structural class relies on the availability of efficient and versatile methods for the generation of large and diversified libraries of macrocyclic peptide-based molecules. To this end, we have developed a methodology for the synthesis of hybrid organo-peptide macrocycles via the cyclization of ribosomally derived polypeptide sequences with non-peptidic organic linkers. This strategy relies on the chemoselective and bioorthogonal ligation of azide/hydrazide-based “synthetic precursors” with intein-fused polypeptides harboring a side-chain alkyne functionality. This macrocyclization approach was found to proceed with high efficiency across a range of different target peptide sequences spanning 4–12 residues as well as across multiple mono- and diaryl-based synthetic precursors. This versatility combined with the possibility to integrate non-proteinogenic scaffolds into genetically encoded peptide sequences makes this methodology of particularly high value toward the creation and screening of highly diverse libraries of peptide-based macrocycles.

Key words

Macrocyclic peptide Organo-peptide hybrids Azide–alkyne Huisgen Cycloaddition Click chemistry Intein Intein-mediated ligation Bioorthogonal ligation 

Notes

Acknowledgments

This work was supported by the US National Science Foundation grant CHE-1112342 awarded to R.F. J.M.S. is grateful to the NSF Graduate Research Fellowship Program for the financial support. MS instrumentation was supported by the US National Science Foundation grants CHE-0840410 and CHE-0946653.

References

  1. 1.
    Robinson JA, Demarco S, Gombert F, Moehle K, Obrecht D (2008) The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today 13:944–951PubMedCrossRefGoogle Scholar
  2. 2.
    Driggers EM, Hale SP, Lee J, Terrett NK (2008) The exploration of macrocycles for drug discovery—an underexploited structural class. Nat Rev Drug Discov 7:608–624PubMedCrossRefGoogle Scholar
  3. 3.
    Marsault E, Peterson ML (2011) Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J Med Chem 54:1961–2004PubMedCrossRefGoogle Scholar
  4. 4.
    Smith JM, Frost JR, Fasan R (2013) Emerging strategies to access peptide macrocycles from genetically encoded polypeptides. J Org Chem 78:3525–3531PubMedCrossRefGoogle Scholar
  5. 5.
    Hayashi Y, Morimoto J, Suga H (2012) In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors. ACS Chem Biol 7:607–613PubMedCrossRefGoogle Scholar
  6. 6.
    Morimoto J, Hayashi Y, Suga H (2012) Discovery of macrocyclic peptides armed with a mechanism-based warhead: isoform-selective inhibition of human deacetylase SIRT2. Angew Chem Int Ed 51:3423–3427CrossRefGoogle Scholar
  7. 7.
    Dias RL, Fasan R, Moehle K, Renard A, Obrecht D, Robinson JA (2006) Protein ligand design: from phage display to synthetic protein epitope mimetics in human antibody Fc-binding peptidomimetics. J Am Chem Soc 128:2726–2732PubMedCrossRefGoogle Scholar
  8. 8.
    Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA (2007) Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 365:1533–1544PubMedCrossRefGoogle Scholar
  9. 9.
    Fairlie DP, Tyndall JD, Reid RC, Wong AK, Abbenante G, Scanlon MJ, March DR, Bergman DA, Chai CL, Burkett BA (2000) Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing. J Med Chem 43:1271–1281PubMedCrossRefGoogle Scholar
  10. 10.
    Satoh T, Li S, Friedman TM, Wiaderkiewicz R, Korngold R, Huang Z (1996) Synthetic peptides derived from the fourth domain of CD4 antagonize off function and inhibit T cell activation. Biochem Biophys Res Commun 224:438–443PubMedCrossRefGoogle Scholar
  11. 11.
    Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305:1466–1470PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Rezai T, Yu B, Millhauser GL, Jacobson MP, Lokey RS (2006) Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J Am Chem Soc 128:2510–2511PubMedCrossRefGoogle Scholar
  13. 13.
    Gudmundsson OS, Vander Velde DG, Jois SD, Bak A, Siahaan TJ, Borchardt RT (1999) The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability. J Pept Res 53:403–413PubMedCrossRefGoogle Scholar
  14. 14.
    White CJ, Yudin AK (2011) Contemporary strategies for peptide macrocyclization. Nat Chem 3:509–524PubMedCrossRefGoogle Scholar
  15. 15.
    Frost JR, Smith JM, Fasan R (2013) Design, synthesis, and diversification of ribosomally derived peptide macrocycles. Curr Opin Struct Biol 23:571–580PubMedCrossRefGoogle Scholar
  16. 16.
    Scott CP, Abel-Santos E, Wall M, Wahnon DC, Benkovic SJ (1999) Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci U S A 96:13638–13643PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Tavassoli A, Lu Q, Gam J, Pan H, Benkovic SJ, Cohen SN (2008) Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. ACS Chem Biol 3:757–764PubMedCrossRefGoogle Scholar
  18. 18.
    Millward SW, Takahashi TT, Roberts RW (2005) A general route for post-translational cyclization of mRNA display libraries. J Am Chem Soc 127:14142–14143PubMedCrossRefGoogle Scholar
  19. 19.
    Schlippe YV, Hartman MC, Josephson K, Szostak JW (2012) In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors. J Am Chem Soc 134:10469–10477PubMedCrossRefGoogle Scholar
  20. 20.
    Hipolito CJ, Suga H (2012) Ribosomal production and in vitro selection of natural product-like peptidomimetics: the FIT and RaPID systems. Curr Opin Chem Biol 16:196–203PubMedCrossRefGoogle Scholar
  21. 21.
    Hofmann FT, Szostak JW, Seebeck FP (2012) In vitro selection of functional lantipeptides. J Am Chem Soc 134:8038–8041PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Levengood MR, Knerr PJ, Oman TJ, van der Donk WA (2009) In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids. J Am Chem Soc 131:12024–12025PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Maksimov MO, Pan SJ, Link AJ (2012) Lasso peptides: structure, function, biosynthesis, and engineering. Nat Prod Rep 29:996–1006PubMedCrossRefGoogle Scholar
  24. 24.
    Smith JM, Vitali F, Archer SA, Fasan R (2011) Modular assembly of macrocyclic organo-peptide hybrids using synthetic and genetically encoded precursors. Angew Chem Int Ed 50:5075–5080CrossRefGoogle Scholar
  25. 25.
    Liu CC, Schultz PG (2010) Adding new chemistries to the genetic code. Annu Rev Biochem 79:413–444PubMedCrossRefGoogle Scholar
  26. 26.
    Deiters A, Schultz PG (2005) In vivo incorporation of an alkyne into proteins in Escherichia coli. Bioorg Med Chem Lett 15:1521–1524PubMedCrossRefGoogle Scholar
  27. 27.
    Young TS, Ahmad I, Yin JA, Schultz PG (2010) An enhanced system for unnatural amino acid mutagenesis in E. coli. J Mol Biol 395:361–374PubMedCrossRefGoogle Scholar
  28. 28.
    Frost JR, Vitali F, Jacob NT, Brown MD, Fasan R (2013) Macrocyclization of organo-peptide hybrids through a dual bio-orthogonal ligation: insights from structure-reactivity studies. Chembiochem 14:147–160PubMedCrossRefGoogle Scholar
  29. 29.
    Uttamapinant C, Tangpeerachaikul A, Grecian S, Clarke S, Singh U, Slade P, Gee KR, Ting AY (2012) Fast, cell-compatible click chemistry with copper-chelating azides for biomolecular labeling. Angew Chem Int Ed 51:5852–5856CrossRefGoogle Scholar
  30. 30.
    Deiters A, Cropp TA, Mukherji M, Chin JW, Anderson JC, Schultz PG (2003) Adding amino acids with novel reactivity to the genetic code of Saccharomyces cerevisiae. J Am Chem Soc 125:11782–11783PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of ChemistryUniversity of RochesterRochesterUSA

Personalised recommendations